NCT05873205 2026-03-02
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT05284032 2024-07-31
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
University of Virginia
Phase EARLY_PHASE1 Terminated